38 Results
Sort By:
Published on December 7, 2018
Illumina said it will provide a new high-density genotyping array at no charge to the NIH’s All of Us Research Program. The sequencing giant’s Infinium Global Diversity Array will enable the processing of up to 1 million samples by the three genome centers that were awarded a total $28.6 million…
Published on July 20, 2018
A coalition of entrepreneurs, researchers, and biopharma industry advocates in suburban Westchester County, NY, is working to create a “hub” that would link them with partners in and outside the county, with the goal of advancing research and development of new treatments for rare diseases. The Westchester Biotech Project—a not-for-profit…
Published on May 7, 2018
Geisinger Health said it will begin offering DNA sequencing to patients as part of its routine clinical care, building upon precision medicine research efforts that include a successful collaboration with Regeneron Pharmaceuticals. Geisinger’s clinical DNA sequencing efforts will kick off with a 1,000-patient pilot program within the next six months.…
Published on January 8, 2018
Investigators at Laval University in Quebec have just released data confirming the polygenic contribution of early-onset coronary artery disease (EOCAD). The researchers found that a polygenic risk score—based on multiple genetic differences—predicted significantly more cases of early-onset heart disease than standard tests for single genetic defects. Findings from the new…
Published on November 15, 2017
The Regeneron Genetics Center (RGC) has sequenced 250,000 exomes sequenced since its creation three years ago—with a vision of sequencing up to double that number. RGC, a wholly-owned subsidiary of Regeneron Pharmaceuticals established in 2014, has increased its sequencing rate since then to 200,000 exomes per year, with plans to…
Published on August 11, 2017
Four-year-old genetic testing company Color Genomics has announced its first foray outside the hereditary cancer screening area with the launch of a familial hypercholesterolemia (FH) screening test. FH is an hereditary genetic disorder that manifests in very high levels of cholesterol and elevated levels of LDL—or “bad” cholesterol—in the blood.…
Published on July 18, 2017
Agena Bioscience said today it will co-promote its MassARRAY® DX clinical diagnostics technology with HeartGenetics' CE-IVD marked products for cardiovascular testing, through a co-marketing alliance whose value was not disclosed. Agena’s MassARRAY DX, which is also CE-IVD marked, is a non-fluorescent detection platform utilizing mass spectrometry to accurately measure PCR-derived…
Published on December 22, 2016
Regeneron Pharmaceuticals and Geisinger Health System today published in Science details of their DiscovEHR precision medicine collaboration that is leveraging large-scale sequencing and de-identified data from electronic health records to guide genomic medicine and genomics-guided therapeutic discoveries. Geisinger is a healthcare system that provides coverage to people in parts of…